| Drug Name |
Aprepitant |
| Drug ID |
BADD_D00157 |
| Description |
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). |
| Indications and Usage |
For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents). |
| Marketing Status |
approved; investigational |
| ATC Code |
A04AD12 |
| DrugBank ID |
DB00673
|
| KEGG ID |
D02968
|
| MeSH ID |
D000077608
|
| PubChem ID |
135413536
|
| TTD Drug ID |
D0GU4K
|
| NDC Product Code |
50370-0048; 59285-015; 66039-851; 73005-0009; 47426-201; 68462-112; 55111-892; 56125-634; 65085-0043; 66039-880; 13668-593; 0006-0461; 0006-3066; 0006-3862; 47426-401; 13612-0024; 50370-0022; 68462-584; 68462-585; 56125-632; 64567-0021; 0006-0464; 68462-583; 0781-2321; 0781-2322; 0781-2323; 56125-633; 73309-380; 0781-4063; 0006-0462; 50370-0038; 65372-1169; 13668-591; 13668-592; 65977-0024; 72643-020; 13668-594 |
| UNII |
1NF15YR6UY
|
| Synonyms |
Aprepitant | MK 869 | MK 0869 | MK-0869 | MK0869 | MK-869 | MK869 | (2R)-(1R)-3,5-bis(Trifluoromethylphenyl)ethoxy)-(3S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazole)methyl-morpholine | MK 0517 | MK0517 | MK-0517 | (1-(3,5-bis(Trifluoromethyl)phenyl)ethoxy)-3-(fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine | Emend | L 754030 | L-754030 | L754030 | L 754,030 | L-754,030 | L754,030 |
